New joint venture aims to cover the entire drug discovery process, spanning early drug discovery research through the inception of drug discovery startups.
The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.